| Active, not recruiting |
: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2015-10-29
: - Drug: JNJ 56021927 JNJ 5602192
|
| Suspended |
: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2015-12-07
: - Biological: JNJ-64041809 (Cohort 1A and 1B)
|
| Active, not recruiting |
: A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2014-06-11
: Drug: JNJ-56021927 Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single or
|
| Completed |
: IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
: Prostatic Neoplasms, Castration-Resistant
: 2017-01-09
: - Drug: Atezolizumab Atezolizuma
|
| Withdrawn |
: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2016-09-15
: - Drug: JNJ-809 JNJ-809 (1*10^9)
|
| Not yet recruiting |
: Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
: Prostatic Neoplasms, Castration-Resistant
: 2016-07-19
: Drug: Xofigo (Radium-223 dichloride, BAY88-8223 Xofigo is indicated for the treatment of patients with c
|
| Completed |
: Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
: Prostatic Neoplasms, Castration-Resistant
: 2016-06-14
: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Xofigo treatment will be performed according to the pr
|
| Completed |
: Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
: Prostatic Neoplasms, Castration-Resistant
: 2015-05-19
: Drug: Radium-223-dichloride (Xofigo, BAY88-8223) according to Summary of Product Characteristics
|
| Completed |
: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
: Prostatic Neoplasms, Castration-Resistant
: 2014-07-29
: - Drug: BI 836845
- Drug: Enzalutamide
|
| Not yet recruiting |
: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer
: - Prostatic Neoplasms, Castration-Resistant
- Prostate Cancer
: 2016-11-14
: - Other: Exercise Intervention V
|
